dolutegravir

an HIV-1 integrase inhibitor

Also Known As:

(4R,12aS)-N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide; (4R,9aS)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid- 2,4 difluorobenzylamide; (4S,12aR)-N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide; (4S,12aS)-N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide; GSK 1349572A; GSK-1349572; GSK-1349572A; GSK1349572A; S-GSK1349572; Tivicay; Tivicay PD; dolutegravir S,R isomer; dolutegravir S,S-isomer; dolutegravir sodium; dolutegravir sodium monohydrate

Networked: 506 relevant articles (37 outcomes, 96 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
- Fused-Ring Heterocyclic Compounds
  - 3-Ring Heterocyclic Compounds
    - dolutegravir: 506

Experts

1.	Maartens, Gary: 12 articles (03/2022 - 07/2017)
2.	Wynne, Brian: 12 articles (01/2022 - 11/2013)
3.	Sax, Paul E: 12 articles (01/2021 - 03/2016)
4.	Hill, Andrew: 11 articles (12/2021 - 01/2018)
5.	Khoo, Saye: 9 articles (01/2022 - 04/2016)
6.	Lamorde, Mohammed: 8 articles (01/2022 - 01/2019)
7.	Calmy, Alexandra: 8 articles (11/2020 - 01/2017)
8.	Sokhela, Simiso: 7 articles (03/2022 - 01/2019)
9.	Aboud, Michael: 7 articles (01/2022 - 12/2017)
10.	Myer, Landon: 7 articles (01/2022 - 01/2019)

Related Diseases

1.	Infections 01/01/2016 - "Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials." 01/01/2021 - "Dolutegravir in combination with NRTIs was effective in treating patients with HIV-1 infection, including those with extensive NRTI resistance in whom no NRTIs were predicted to have activity. " 04/30/2020 - "Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study." 10/01/2019 - "The aim of this study was to compare the tolerability and viro-immunological efficacy of dolutegravir-based regimens (DTG group) with regimens based on EVG, RAL, PI or NNRTI (NODTG group) in patients with acute HIV-1 infections (AHI). " 01/01/2022 - "WHO recommends dolutegravir (DTG) based regimens as first-line treatment for HIV-1 infection. "
2.	HIV Infections (HIV Infection) 09/01/2014 - "The high efficacy of dolutegravir in MDMs (cells with limited metabolism) has relevant clinical implications in light of the role of MDMs in the transmission of HIV infection and dissemination in different body compartments." 01/01/2018 - "The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India." 01/01/2019 - "Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)." 11/24/2023 - "Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria." 09/01/2023 - "Dolutegravir (DTG) is a recommended first-line regimen for all people with Human Immunodeficiency Virus (HIV) infection. "
3.	Acquired Immunodeficiency Syndrome (AIDS) 10/01/2023 - "Dolutegravir (DTG) has been the first-line drug in many human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) guidelines for the treatment of naïve and experienced HIV-infected individuals, which calls for cost-effective and convenient methods for quantitative detection of DTG in human plasma for pharmacokinetic studies and patient adherence evaluation. " 10/01/2022 - "Virologic Response Following a Switch to Dolutegravir-based Regimen in People Living with HIV/AIDS at a Tertiary Care Center in Nepal." 01/01/2022 - "International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) P1093 is a phase 1-2 ongoing multicentre, open-label, non-comparative study of dolutegravir. " 01/01/2022 - "87 sites that began using dolutegravir in 11 LMICs in the Asia-Pacific; Caribbean, Central and South America network for HIV epidemiology (CCASAnet); and sub-Saharan African regions of the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium. " 01/01/2021 - "With the continued promotion of dolutegravir-based HIV regimens as the preferred option for the treatment of HIV in President's Emergency Plan for AIDS Relief (PEPFAR) supported HIV treatment programs in Africa, clinicians must be aware of the potentially life-threatening consequences of switching antiretroviral regimens. "
4.	Neural Tube Defects (Exencephaly) 01/01/2019 - "The unexpected identification of a neural tube defect (NTD) safety signal with preconception dolutegravir (DTG) exposure in the Botswana Tsepamo birth outcomes study brought into sharp focus the need for reliable data on use of new antiretrovirals in pregnancy, improved pharmacovigilance systems to evaluate safety of new drugs being introduced into populations including women of reproductive potential, and balanced risk-benefit messaging when a safety signal is identified. " 06/29/2023 - "In 2018, the Botswana Tsepamo Study reported a nine-fold increased risk of neural tube defects in infants whose mothers were treated with dolutegravir (DTG) from the time of conception. " 01/01/2023 - "A study from Botswana identified an increased risk of neural tube defects (NTDs) in infants of mothers with HIV who were treated with dolutegravir around the time of conception. " 01/01/2023 - "A large surveillance study in Botswana previously raised concerns about an association between pre-conception dolutegravir and neural tube defects. " 01/01/2022 - "The animal studies available demonstrate that in utero dolutegravir exposure can be associated with neural tube defects. "
5.	Weight Gain 01/01/2020 - "The policy involving ART initiation with a dolutegravir-based regimen in women intending pregnancy was cost-effective in 87% of our setting scenarios and this finding was robust in various sensitivity analyses, including around the potential negative effects of weight gain. " 01/01/2022 - ""It's only fatness, it doesn't kill": a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda." 10/01/2023 - "Impact of weight gain with dolutegravir on antiretroviral adherence and viral suppression in four African countries." 09/01/2023 - "Weight gain in patients starting Dolutegravir-based ART according to baseline CD4 count after 48 weeks of follow up." 07/01/2023 - "Although dolutegravir (DTG) has a favorable metabolic profile, it has been linked to excess weight gain. "

Related Drugs and Biologics

1.	efavirenz (Sustiva)
2.	Raltegravir Potassium
3.	Lamivudine (Epivir)
4.	Integrase Inhibitors
5.	Ritonavir (Norvir)
6.	Darunavir (Prezista)
7.	elvitegravir
8.	Antiviral Agents (Antivirals)
9.	Racivir
10.	Maraviroc

Related Therapies and Procedures

1.	Therapeutics
2.	Art Therapy
3.	Highly Active Antiretroviral Therapy (HAART)
4.	Inhalation Administration
5.	Aftercare (After-Treatment)